X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761289
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761289
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cdsco-approves-astrazenecas-anti-liver-cancer-drug-combination/articleshow/100683439.cms
https://www.ema.europa.eu/en/documents/overview/tremelimumab-astrazeneca-epar-medicine-overview_en.pdf
https://www.ema.europa.eu/en/documents/overview/imjudo-epar-medicine-overview_en.pdf
https://www.ema.europa.eu/en/documents/overview/imjudo-epar-medicine-overview_en.pdf
https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-imjudo-approved-in-the-eu-for-patients-with-advanced-liver-and-non-small-cell-lung-cancers.html
https://www.fiercepharma.com/pharma/bristol-myers-doubles-down-immuno-oncology-patent-fight-az-time-targeting-imjudo
https://www.pharmaceutical-technology.com/news/japan-astrazeneca-liver-lung-cancers/
https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-imjudo-recommended-for-approvals-in-eu.html
https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-and-imjudo-approved-in-us-for-lung-cancer.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761270
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761289
https://www.fiercepharma.com/marketing/long-last-astrazenecas-tremelimumab-snags-first-approval-only-ever-crowded-liver-cancer
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761289
https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-and-tremelimumab-with-chemotherapy-demonstrated-sustained-survival-benefit-in-metastatic-non-small-cell-lung-cancer.html
https://endpts.com/after-18-years-in-development-astrazenecas-ctla-4-antibody-gets-the-red-carpet-treatment-at-the-fda/
https://www.fiercepharma.com/pharma/astrazeneca-climbs-a-himalya-to-find-ill-fated-treme-a-place-alongside-imfinzi-liver-cancer
https://www.fiercepharma.com/marketing/astrazeneca-s-imfinzi-immunotherapy-s-first-win-bile-duct-cancer-merck-s-keytruda-behind
https://www.fiercepharma.com/marketing/cancer-immunotherapy-market-up-for-disruption-as-astrazeneca-regeneron-sanofi-cheaper
https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-improves-survival-in-nsclc-in-poseidon.html
https://www.fiercepharma.com/pharma/has-astrazeneca-finally-found-a-place-for-long-plagued-i-o-candidate-tremelimumab
https://www.fiercepharma.com/pharma/astrazeneca-s-tremelimumab-records-another-miss-as-imfinzi-combo-strikes-out-small-cell-lung
http://www.pharmatimes.com/news/imfinzi,_tremelimumab_combo_flunks_sclc_trial_1329473
https://www.biopharmadive.com/news/astrazeneca-imfinzi-danube-study-bladder-cancer/573657/
http://www.pharmatimes.com/news/imfinzi_cancer_combo_falls_short_in_danube_trial_1328144
Market Place
Share 
